Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML)

Trial Profile

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Chronic myeloid leukaemia; Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top